Compare HELE & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HELE | TRDA |
|---|---|---|
| Founded | 1968 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 390.4M | 481.6M |
| IPO Year | 1996 | 2021 |
| Metric | HELE | TRDA |
|---|---|---|
| Price | $14.99 | $11.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $22.00 | $20.00 |
| AVG Volume (30 Days) | ★ 459.8K | 188.4K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,478,845,000.00 | $25,421,000.00 |
| Revenue This Year | N/A | $39.97 |
| Revenue Next Year | $0.72 | $53.29 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.03 | $4.93 |
| 52 Week High | $54.25 | $13.99 |
| Indicator | HELE | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 32.26 | 48.02 |
| Support Level | N/A | $9.78 |
| Resistance Level | $19.26 | $12.56 |
| Average True Range (ATR) | 0.71 | 0.88 |
| MACD | -0.12 | -0.11 |
| Stochastic Oscillator | 13.24 | 27.21 |
Helen Of Troy Ltd is a consumer products company offering creative products and solutions for its customers through a diversified portfolio of brands. It has two operating segments: Home and Outdoor segment provides a broad range of consumer products for home activities such as food preparation, cooking, cleaning, and organization; as well as products for outdoor and on-the-go activities such as hydration, food storage, backpacks, and travel gear, and The Beauty and Wellness segment provides beauty and wellness products including mass and prestige market beauty appliances, prestige market liquid-based hair and personal care products, and wellness devices including thermometers, water and air filtration systems, humidifiers, and fans.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.